Case Report: Recurrent Mpox in a Healthcare Worker in Nigeria

Dimie Ogoina Infectious Diseases Unit, Department of Internal Medicine, Niger Delta University/Niger Delta University Teaching Hospital, Yenagoa, Nigeria;

Search for other papers by Dimie Ogoina in
Current site
Google Scholar
PubMed
Close
,
Inestol Oru Oru Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Nigeria;

Search for other papers by Inestol Oru Oru in
Current site
Google Scholar
PubMed
Close
,
Adesola Yinka-Ogunleye Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria;

Search for other papers by Adesola Yinka-Ogunleye in
Current site
Google Scholar
PubMed
Close
,
Chikwe Ihekweazu Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria;

Search for other papers by Chikwe Ihekweazu in
Current site
Google Scholar
PubMed
Close
,
Nnaemeka Ndodo Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria;

Search for other papers by Nnaemeka Ndodo in
Current site
Google Scholar
PubMed
Close
, and
Olusola Aruna International Health Regulations Strengthening Project, Global Operations, UK Health Security Agency, London, United Kingdom

Search for other papers by Olusola Aruna in
Current site
Google Scholar
PubMed
Close
Restricted access

ABSTRACT.

We report the first case of recurrent Mpox from Africa. The patient is a 36-year-old, previously healthy, HIV-negative male healthcare worker who developed two episodes of laboratory-confirmed Mpox in 2017 and 2018, 9 months apart. In both cases, he had prior close contact with confirmed Mpox cases in the hospital setting. On follow-up in 2022, he also reported recurrent postcoital skin eruptions over a previously healed genital scar from the first episode of Mpox. We highlight the need for future studies to investigate the true burden and risk factors for Mpox reinfection, relapse, and recrudescence.

Author Notes

Address correspondence to Dimie Ogoina, Infectious Diseases Unit, Department of Internal Medicine, Niger Delta University/Niger Delta University Teaching Hospital, PMB 100, Yenagoa, Bayelsa, Nigeria. E-mail: dimieogoina@gmail.com

Authors’ addresses: Dimie Ogoina, Infectious Diseases Unit, Department of Internal Medicine, Niger Delta University/Niger Delta University Teaching Hospital, Yenagoa, Nigeria, E-mail: dimieogoina@gmail.com. Inestol Oru Oru, Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Nigeria, E-mail: inetsol28@gmail.com. Adesola Yinka-Ogunleye, Chikwe Ihekweazu, and Nnaemeka Ndodo, Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria, E-mails: adesola.ogunleye@ncdc.gov.ng, cihekweazu@who.int, and nnaemeka.ndodo@ncdc.gov.ng. Olusola Aruna, International Health Regulations Strengthening Project, Global Operations, UK Health Security Agency, London, United Kingdom, E-mail: olusola.aruna@ukhsa.gov.uk.

  • 1.

    McCollum AM , Damon IK , 2014. Human monkeypox. Clin Infect Dis 58: 260267.

  • 2.

    Hammarlund E , Lewis MW , Hanifin JM , Mori M , Koudelka CW , Slifka MK , 2010. Antiviral immunity following smallpox virus infection: a case-control study. J Virol 84: 1275412760.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Crotty S , Felgner P , Davies H , Glidewell J , Villarreal L , Ahmed R , 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171: 49694973.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Adler H et al., 2022. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 22: 11531162.

  • 5.

    Raccagni AR , Clemente T , Ranzenigo M , Cicinelli MV , Castagna A , Nozza S , 2023. Persistent ocular Mpox infection in an immunocompetent individual. Lancet Infect Dis 23: 652653.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Musumeci S , Najjar I , Boffi El Amari E , Schibler M , Jacquerioz F , Yerly S , Renzoni A , Calmy A , Kaiser L , 2023. A case of Mpox reinfection. Clin Infect Dis 77: 135137.

  • 7.

    Golden J , Harryman L , Crofts M , Muir P , Donati M , Gillett S , Irish C , 2023. Case of apparent Mpox reinfection. Sex Transm Infect 99: 283284.

  • 8.

    Zeggagh J , Ferraris O , Salmona M , Tarantola A , Molina JM , Delaugerre C , 2023. Second clinical episode of hMPX virus in a man having sex with men. Lancet 401: 1610.

  • 9.

    Raccagni AR et al., 2023. Two individuals with potential monkeypox virus reinfection. Lancet Infect Dis 23: 522524.

  • 10.

    Álvarez-López P et al., 2023. Suspected case of monkeypox reinfection versus reactivation in a immunocompetent patient, Barcelona, 2022. Int J STD AIDS, doi: 10.1177/09564624231162426.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Rocha SQ , Fonsi M , Tancredi MV , Ramos de Alencar HD , Abbud A , da Silva MH , 2023. Mpox in a couple living with HIV: relapse or reinfection? AIDS Res Hum Retroviruses, doi: 10.1089/aid.2022.0189.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Yinka-Ogunleye A et al., 2019. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis 19: 872879.

  • 13.

    Karem KL , Reynolds M , Braden Z , Lou G , Bernard N , Patton J , Damon IK , 2005. Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol 12: 867872.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Faye O et al., 2018. Genomic characterisation of human monkeypox virus in Nigeria. Lancet Infect Dis 3099: 231117.

  • 15.

    Negi N , Maurya SP , Singh R , Das BK , 2022. An update on host immunity correlates and prospects of re-infection in COVID-19. Int Rev Immunol 41: 367392.

  • 16.

    Avery RK , Pasternack MS , 1997. Approach to adult patients with recurrent infections. Cleve Clin J Med 64: 249257.

  • 17.

    Grinde B , 2013. Herpesviruses: latency and reactivation—viral strategies and host response. J Oral Microbiol 5: 22766.

  • 18.

    Ogoina D et al., 2020. Clinical course and outcome of human monkeypox in Nigeria. Clin Infect Dis 71: E210E214.

  • 19.

    Fenner F , Henderson DA , Arita I , Jezek Z , Ladnyi ID , 1988. Smallpox and Its Eradication. Geneva, Switzerland: World Health Organization.

  • 20.

    Lum F-M , Torres-Ruesta A , Tay MZ , Lin RTP , Lye DC , Rénia L , Ng LFP , 2022. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol 22: 597613.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Karem KL , Reynolds M , Hughes C , Braden Z , Nigam P , Crotty S , Glidewell J , Ahmed R , Amara R , Damon IK , 2007. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol 14: 13181327.

    • PubMed
    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 1778 1778 51
Full Text Views 259 259 1
PDF Downloads 96 96 1
 
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save